Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;7(1):3-23.
doi: 10.2174/2211738507666190122111224.

Drug Combinations in Breast Cancer Therapy

Funmilola A Fisusi  1   2 , Emmanuel O Akala  1
Affiliations
Review

Drug Combinations in Breast Cancer Therapy

Funmilola A Fisusi et al. Pharm Nanotechnol. 2019.

Abstract

Breast cancer therapy involves a multidisciplinary approach comprising surgery, radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires maximum therapeutic efficacy, with minimal undesirable effects to ensure a good quality of life for patients. The carefully selected combination of therapeutic interventions provides patients with the opportunity to derive maximum benefit from therapy while minimizing or eliminating recurrence, resistance and toxic effects, as well as ensuring that patients have a good quality of life. This review discusses therapeutic options for breast cancer treatments and various combinations that had been previously exploited. The review will also give an insight into the potential application of the nanotechnology platform for codelivery of therapeutics in breast cancer therapy.

Keywords: Breast cancer; chemotherapy; combination therapy; early breast cancer; metastatic breast cancer; nanotechnology; radiotherapy; surgery..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Classification of breast cancer according to molecular subclasses. Key: BL = Basal-like; LA = Luminal-A; LB = Luminal-B; HER2+ = Human epidermal growth factor 2 (HER2)-positive/HER2-enriched/HER2-overexpressing BC; NL = Normal-like tumors.
Fig. (2)
Fig. (2)
Schematic representation of treatment strategies for breast cancer.
Fig. (3)
Fig. (3)
Schematic representation of main therapeutic combinations in BC treatment. Key: Chemo = chemotherapy; Horm = hormononal therapy; Immun = immunotherapy.
See this image and copyright information in PMC

References

    1. Harbeck N., Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. - PubMed
    1. Torre L.A., Siegel R.L., Ward E.M., Jemal A. Global cancer incidence and mortality rates and trends: an update. Cancer Epidemiol. Biomarkers Prev. 2016;25(1):16–27. - PubMed
    1. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. - PubMed
    1. Prat A., Pineda E., Adamo B., et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26–S35. - PubMed
    1. Matta J., Ortiz C., Encarnacion J., Dutil J., Suarez E. Variability in dna repair capacity levels among molecular breast cancer subtypes: triple negative breast cancer shows lowest repair. Int. J. Mol. Sci. 2017;18(7) - PMC - PubMed

Publication types

MeSH terms

Substances